Oorsprong van het eerstegraads netwerk van Edward F. Nemeth
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 27 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Edward F. Nemeth via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| CAMBREX CORPORATION | Pharmaceuticals: Generic | Director/Board Member | |
| CELGENE | Biotechnology | Director/Board Member | |
| ABRDN HEALTHCARE INVESTORS | Investment Trusts/Mutual Funds | Director/Board Member | |
| ABRDN LIFE SCIENCES INVESTORS | Investment Trusts/Mutual Funds | Director/Board Member | |
| BIOGEN INC. | Pharmaceuticals: Major | Sales & Marketing | |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Chief Executive Officer | |
| SAREPTA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| PHASEBIO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| SINTX TECHNOLOGIES, INC. | Medical Specialties | Compliance Officer Chief Operating Officer Comptroller/Controller/Auditor | |
| RADIUS HEALTH, INC. | Biotechnology | Chief Executive Officer Corporate Officer/Principal | |
| TETRALOGIC PHARMACEUTICALS CORPORATION | Pharmaceuticals: Major | Director/Board Member | |
Q Therapeutics, Inc.
 Q Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman in March 2002 and is headquartered in Salt Lake City, UT. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| Hatteras Venture Affiliates III LP | Investment Managers | Corporate Officer/Principal | |
Viamet Pharmaceuticals Corp.
 Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member | |
| ABRDN WORLD HEALTHCARE FUND | Investment Trusts/Mutual Funds | Director/Board Member | |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Investment Managers | Corporate Officer/Principal | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Corporate Officer/Principal | |
Tekla Capital Management LLC
 Tekla Capital Management LLC Investment ManagersFinance Tekla Capital Management LLC is an independent, SEC-registered investment advisor headquartered in Boston, Massachusetts. Formerly known as Hambrecht & Quist Capital Management LLC, the firm serves as an investment adviser for four closed-end funds – Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. | Investment Managers | Director/Board Member | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| University of Utah | College/University | Masters Business Admin Graduate Degree Masters Business Admin Masters Business Admin Undergraduate Degree | |
| Bates College | College/University | Undergraduate Degree | |
| Yale University | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree | |
| University of Illinois | College/University | Undergraduate Degree Graduate Degree | |
| Utah State University | College/University | Undergraduate Degree Graduate Degree Graduate Degree | |
Gilead Connecticut, Inc.
 Gilead Connecticut, Inc. Pharmaceuticals: MajorHealth Technology Gilead Connecticut, Inc. manufactures pharmaceuticals and biotechnology chemicals. The firm develops a pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. It focuses on the development of novel kinase inhibitors for the treatment of cancer, autoimmune, and inflammatory diseases. The company was founded in 2000 and is headquartered in Foster City, CA. | Pharmaceuticals: Major | Director/Board Member | |
Whitehead Institute for Biomedical Research
 Whitehead Institute for Biomedical Research Miscellaneous Commercial ServicesCommercial Services Whitehead Institute for Biomedical Research provides research and technology services. Its services include biomedical, genomics, and genetics for students. The company was founded by Edwin C. Whitehead in 1982 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member | |
Beth Israel Deaconess Medical Center, Inc.
 Beth Israel Deaconess Medical Center, Inc. Hospital/Nursing ManagementHealth Services Beth Israel Deaconess Medical Center provides medical services. It offers patient care, biomedical research, teaching, and community services. It also provides organ transplantation, breast cancer care, and cardiac surgery services. The company was founded in 1896 and is headquartered in Boston, MA. | Hospital/Nursing Management | Director/Board Member | |
Prolexys Pharmaceuticals, Inc.
 Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Pharmaceuticals: Major | Chief Executive Officer | |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Pharmaceuticals: Major | Director/Board Member | |
Hatteras Venture Partners
 Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | Investment Managers | Private Equity Investor | |
Embrella Cardiovascular, Inc.
 Embrella Cardiovascular, Inc. Miscellaneous Commercial ServicesCommercial Services Embrella Cardiovascular, Inc. develops proprietary systems for embolic cerebral protection during cardiovascular procedures. The company was founded by Judith T. Carpenter and Jeffrey Francis O'Donnell, Sr. in 2007 and is headquartered in Wayne, PA. | Miscellaneous Commercial Services | Director/Board Member | |
Gulf of Maine Research Institute
 Gulf of Maine Research Institute Miscellaneous Commercial ServicesCommercial Services Gulf of Maine Research Institute is a research institute founded in 1994 that provides collaborative solutions to ocean challenges. The non-profit company is based in Portland, ME. | Miscellaneous Commercial Services | Director/Board Member | |
Zeneca Pharmaceuticals
 Zeneca Pharmaceuticals Pharmaceuticals: MajorHealth Technology Zeneca Pharmaceuticals manufactures medicines. | Pharmaceuticals: Major | Corporate Officer/Principal | |
NPS Allelix Corp.
 NPS Allelix Corp. Pharmaceuticals: MajorHealth Technology NPS Allelix Corp. develops protein therapeutics and neuropharmaceuticals. It provides research and development services in the physical, engineering, and life sciences. The company was founded in 1988 and is headquartered in Mississauga, Canada. | Pharmaceuticals: Major | Investor Relations Contact | |
| SYROS PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
| LIPOCINE INC. | Pharmaceuticals: Major | Director of Finance/CFO Comptroller/Controller/Auditor | |
Navigen, Inc.
 Navigen, Inc. Pharmaceuticals: MajorHealth Technology Navigen, Inc. operates as a drug discovery and development company. The company was founded by Hunter Jackson and is headquartered in Salt Lake City, UT. | Pharmaceuticals: Major | Founder Director/Board Member Director/Board Member Comptroller/Controller/Auditor | |
| ABRDN HEALTHCARE OPPORTUNITIES FUND | Investment Trusts/Mutual Funds | Director/Board Member | |
| REVOLUTION MEDICINES, INC. | Pharmaceuticals: Other | Director/Board Member | |
| KALEIDO BIOSCIENCES, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Life Sciences Cares
 Life Sciences Cares Miscellaneous Commercial ServicesCommercial Services Life Sciences Cares operates an organization aimed at eradicating poverty. The private company is based in Cambridge and was founded by Robert J. Perez. | Miscellaneous Commercial Services | Director/Board Member | |
| ELOXX PHARMACEUTICALS, INC. | Biotechnology | Chief Executive Officer Chief Executive Officer | |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
| GLOBAL BLOOD THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 50 |
| Canada | 2 |
Sectoraal
| Health Technology | 30 |
| Consumer Services | 7 |
| Commercial Services | 6 |
| Finance | 6 |
| Miscellaneous | 5 |
Operationeel
| Director/Board Member | 123 |
| Corporate Officer/Principal | 50 |
| Chairman | 40 |
| Independent Dir/Board Member | 28 |
| Chief Executive Officer | 21 |
Sterkste connecties
| Insiders | |
|---|---|
| Calvin Stiller | 38 |
| Michael Bonney | 32 |
| N. Coles | 30 |
| Douglas Reed | 27 |
| Joseph Klein | 24 |
| Peter G. Tombros | 18 |
| Robert E. Ward | 13 |
| Morgan Brown | 12 |
| Gerard Michel | 9 |
| Rachel R. Selisker | 8 |
| Thomas Parks | 7 |
| Juergen Lasowski | 7 |
| David L. Clark | 7 |
| Gregory C. Williams | 6 |
| Gordon G. Esplin | 6 |
- Beurs
- Insiders
- Edward F. Nemeth
- Bedrijfsconnecties
